首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Flt3L |
| Uniprot No | P49771 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-184aa |
| 氨基酸序列 | TQDCSFQHSPISSDFAVKIRELSDYLLQDYPVTVASNLQDEELCGALWRL VLAQRWMERLKTVAGSKMQGLLERVNTEIHFVTKCAFQPPPSCLRFVQTN ISRLLQETSEQLVALKPWITRQNFSRCLELQCQPDSSTLPPPWSPRPLEA TAPTAPQP |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3-4条关于Flt3L重组蛋白的参考文献概览：
1. **"Flt3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors"**
- 作者：Maraskovsky E. 等(1996)
- 摘要：研究证明Flt3L重组蛋白可显著促进小鼠和人体内树突状细胞(DC)前体的扩增，为免疫治疗提供新策略。
2. **"Hematologic effects of Flt3 ligand in vivo in mice"**
- 作者：Brasel K. 等(1996)
- 摘要：通过动物实验发现，Flt3L注射可剂量依赖性增加骨髓、脾脏中的造血干细胞和DC数量，提示其调节造血系统的作用。
3. **"Flt3 ligand enhances the immunogenicity of a HPV16 E7 peptide-based vaccine in vivo"**
- 作者：Mach N. 等(2000)
- 摘要：将Flt3L作为疫苗佐剂可增强HPV抗原特异性T细胞应答，证实其在增强疫苗效果中的潜在应用。
4. **"Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine via expansion of dendritic cell subsets"**
- 作者：Dhodapkar M.V. 等(2014)
- 摘要：联合使用Flt3L与靶向DC疫苗可显著提升肿瘤抗原特异性免疫应答，为癌症免疫联合治疗提供依据。
注：以上摘要为简化概括，实际文献需通过PubMed等数据库获取完整信息。
Flt3 ligand (Flt3L) is a naturally occurring cytokine critical for hematopoietic and immune system regulation. It binds to the FMS-like tyrosine kinase 3 (Flt3) receptor, a type III receptor tyrosine kinase expressed on early hematopoietic progenitors, dendritic cells (DCs), and certain stem cells. Flt3L plays a key role in promoting the proliferation, differentiation, and survival of these cells, particularly DCs and lymphoid/myeloid precursors. Its absence leads to impaired immune responses due to reduced DC populations.
Recombinant Flt3L protein is engineered using biotechnological methods, often through mammalian or bacterial expression systems, to mimic the biological activity of the native protein. The recombinant form typically retains the receptor-binding domains required for activating Flt3 signaling pathways, which include MAPK, PI3K/Akt, and STAT5. driving cell cycle progression and lineage-specific development.
In research and therapeutics, recombinant Flt3L is widely used to expand DC populations in vitro or in vivo, enhancing antigen presentation and antitumor immunity. It has shown promise in cancer immunotherapy, vaccine adjuvants, and hematopoietic recovery post-chemotherapy. Clinical trials explore its potential in mobilizing DCs for tumor vaccines or combining it with checkpoint inhibitors to amplify immune responses. However, excessive Flt3L may risk unintended proliferation of malignant cells in hematologic disorders, requiring careful dosing.
As a tool, recombinant Flt3L is valued for its purity, consistency, and scalability, often tagged with His or Fc sequences for simplified purification and extended half-life. Its applications span immunology, oncology, and regenerative medicine, reflecting its central role in modulating innate and adaptive immunity.
×
